Featured
Pivotal Trial of EndeavorRx® in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes
Read More →
Akili Announces ADHD Expert Dr. Scott Kollins to Join as Chief Medical Officer
Read More →
Akili Reports Third Quarter 2022 Financial Results and Company Update
Read More →
Financial Industry Veteran Mary Hentges Joins Akili’s Board of Directors
Read More →
Akili to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 10 at 4:30 p.m. ET
Read More →
Akili Launches EndeavorRx® Expedition - A Direct-to-Patient Product Registry
Read More →
Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I
Read More →
The Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients With SLE
Read More →
Akili Announces Public Company Board of Director Nominees
Read More →
Akili Announces Veteran Life Sciences Executive Matt Franklin in Newly Created Role of President and Chief Operating Officer
Read More →
Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox
Read More →
American Journal of Psychiatry Publishes Data Demonstrating Akili's Digital Therapeutic AKL-T03 Improves Cognition in Adults with Major Depressive Disorder When Combined with Antidepressant Medication
Read More →
Akili to Present at Chardan’s Prescription Digital Therapeutics Half-Day Summit
Read More →
Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer
Read More →
Akili to Speak at SXSW 2022 on Building a New Class of Disease-Modifying Digital Therapeutics
Read More →
Akili Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022
Read More →
Akili to Present at Cowen’s 42nd Annual Health Care Conference
Read More →
Akili to Speak on Integrating Digital Therapeutics Into Mainstream Healthcare at DTx West 2022
Read More →
PLOS ONE Publishes Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx ® Activates Systems in Brain Key to Attentional Functioning
Read More →
Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I
Read More →
Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
Read More →
Akili Founders Recognized by Newsweek on Inaugural List of America’s 50 Greatest Disruptors
Read More →
Topline Results from Shionogi Phase 2 Study in Japan Show Akili’s Digital Treatment Was Well-received and Improved Inattention Symptoms in Children with ADHD
Read More →
Akili Announces EndeavorRx® is Now Available on Android™ Devices, Expanding Access for Children with ADHD
Read More →
Akili Enters Strategic Licensing Agreement with TALi, Extending Akili Portfolio and Industry Leadership in Prescription Digital Therapeutics for Cognitive Impairments
Read More →
Akili Releases New Gameplay Features in the First and Only FDA-Cleared Video Game Treatment for Children with ADHD
Read More →
Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics
Read More →
Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Treatment for COVID Brain Fog
Read More →
Researchers Present New Outcome Data for Akili Digital Therapeutic EndeavorRx™ in Pediatric ADHD
Read More →
Akili Announces Appointment of Chief Marketing Officer
Read More →